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Summary
Atopic dermatitis (AD) represents a pruritic, 
non-contagious, chronic or chronically relapsing, 
inammatory skin disease. e course of the dis-
ease may be complicated by bacterial or viral super-
infections. e rst manifestation of the disease and 
further are-ups are due to genetic predisposition 
and also to a variety of further trigger factors. e 
therapy regimen should be adapted to disease symp-
toms that are actually present and consider individ-
ual features of the disease as reported by the pa-
tients or their parents.
is short version of the German guideline on AD 
provides an overview of evidence-based diagnostic 
and treatment options. All recommendations made 
here are the result of a consensus of the scientic 
medical societies, working groups and support 
groups based on scientic data published to date. 
Abstracts and details of the studies cited are provid-
ed in the long version of this guideline (see: www.
awmf.org).
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1. Introduction
1.1. Nomenclature
e committee that produced this guideline agreed 
to use the term „atopic dermatitis“ in this guideline, 
which can be used as a synonym for „atopic eczema“ 
and is also the current term used by patients.
1.2. Methodology
is is the short version of the S2k guideline on 
atopic dermatitis, which was published in a long ver-
sion under register number 013-027 on the AWMF 
website (www.awmf.org), listing original studies 
that led to the recommendations. is guideline is 
an update of the AWMF S2 atopic dermatitis guide-
line published in 2008/2009, in which the method-
ology is presented in more detail [1, 2].
e 2008 guideline was an S2e guideline, for 
which meta-analyses, clinical studies and other sci-
entic investigations were collated through a sys-
tematic literature search in PUBMED and provided 
as a handout to the participants in the consensus 
conference. For the update, the literature search was 
conducted up to January 2014. In addition, individ-
ual studies were supplemented.
e recommendations were produced in an inter-
disciplinary consensus conference using a nominal 
group process. For those interventions for which no 
consensus could be achieved at the consensus con-
ference because of time constraints, a Delphi proce-
dure was used. e recommendation levels of the 
individual recommendations are expressed by stan-
dard formulations in this guideline (Tab. 1) [3].
e content of the German AWMF „Atopic der-
matitis“ guideline“ was harmonized with the corre-
sponding European guideline, which is also being 
updated at the time of publication of this guideline 
[4, 5]. 
1.3. Aims of the guideline
Atopic dermatitis is a common skin disease, both in 
childhood and adolescence and in adults. Because 
of its chronic course and characteristics of this con-
dition, which a¦ects many areas of life with marked 
impairment of quality of life, optimal medical care 
is desirable. 
e general aim of the guideline is to make avail-
able to dermatologists, pediatricians, general phy-
sicians and other doctors involved in o¨ce and hos-
pital treatment of atopic dermatitis an accepted de-
cision-making tool for choosing and implementing 
suitable and su¨cient therapy for patients with 
atopic dermatitis.
1.4. Target group
is guideline is intended for specialists in derma-
tology, pediatric and adolescent medicine, general 
medicine and all groups of physicians whose work 
includes the treatment of atopic dermatitis. It 
should also provide patients and relatives with ac-
curate information for assessing therapeutic inter-
ventions. 
2. Atopic dermatitis – general aspects
2.1. Denition and classication 
Atopic dermatitis is a chronic or chronic relapsing, 
noncontagious skin disease, the classic morphology 
Abbreviations
AGNES  Atopic dermatitis education working 
group, Arbeitsgemeinschaft Neuro-
dermitisschulung
AWMF  Association of the Scienti©c Medical 
 Societies Germany, Arbeitsgemeinschaft 
der Wissenschaftlichen Medizinischen 
Fachgesellschaften
BMG  Federal Ministry of Health, Bundesminis-
terium für Gesundheit
DDG  German Dermatological Society, 
 Deutsche Dermatologische Gesellschaft
EASI Eczema Area and Severity Index
ECP Eosinophilic cationic protein
GKV  Statutory health insurance, Gesetzliche 
Krankenversicherung
IGA Investigator’s Global Assessment
KASK  Drug safety in childhood committee, 
Kommission für Arzneimittelsicherheit 
im Kindesalter
SCORAD Scoring Atopic Dermatitis
STIKO  Vaccine standing committee, Ständige 
Impfkommission
TARC  Thymus and activation regulated 
 chemokine
TPMT Thiopurinmethyltransferase
Tab. 1: Recommendation levels
Positive
 — recommended
 — can be recommended
 — can be considered 
Negative
 —must not be done
 — is not recommended
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and location of which di¦ers depending on age, and 
which is usually associated with severe pruritus. 
More common complications of atopic dermatitis 
include infections such as disseminated impetigi-
nization by Staphylococcus aureus, viral infections 
or fungal infections [6].
Recommendation
— The diagnosis and treatment of atopic dermatitis 
and its complications must be performed by me-
dically quali©ed persons.
2.2. Epidemiology
e cumulative incidence of atopic dermatitis var-
ies between 11 and 21 % in Northern Europe de-
pending on age and region. Point prevalence of 
 10–15 % has been described in Germany. According 
to epidemiologic analyses from Germany, about 
23 % of babies and toddlers, 8 % of schoolchildren 
and 2 to 4 % of adults claim healthcare services be-
cause of atopic dermatitis. In children, atopic der-
matitis is therefore the most common chronic dis-
ease overall [7, 8]. 
2.3. Pathogenesis and genetics
e causes of atopic dermatitis are varied. Both a 
genetic predisposition and numerous trigger factors 
play an important part in the rst manifestation 
and in exacerbations of the disease.
2.3.1. Prevention
Based on understanding of the pathogenesis and 
genetics, general measures for primary prevention 
of atopic dermatitis are recommended. Please re-
fer to the current S3 guideline, „Allergy prevention“ 
[9].
2.3.2. Atopic dermatitis and vaccinations
e vaccine standing committee (STIKO) issues 
recommendations for e¦ective vaccinations in 
Germany. Information can be obtained via the 
Robert Koch Institute (RKI) homepage [10]. ey 
are also published in the „Epidemiological Bulle-
tin“.
Recommendation
— It is recommended that children, adolescents 
and adults with atopic dermatitis are vaccinated 
regularly according to STIKO recommendations. 
In an acute exacerbation, postponement of the 
vaccination until the skin condition has stabilized 
is recommended.
2.4. Manifestations
e skin manifestations of atopic dermatitis di¦er 
according to stage (acute or chronic) and age [6]. 
When the manifestations or course of  inammatory 
skin diseases is untypical, di¦erential diagnoses 
(see 2.7.3) must be investigated, including in child-
hood.
Recommendation
— The di®erent clinical manifestations of atopic 
dermatitis with its age-speci©c features and the 
most important di®erential diagnoses must be 
familiar to the treating physician.
2.5. Course
e course of atopic dermatitis is variable with dis-
ease exacerbations of varying duration and severity. 
e disease can recur oªen. Even slight manifesta-
tions can sometimes result in severe restriction and 
psychological stress. Spontaneous cure is possible 
at any time. However, at least 30 % of all children 
who su¦er from atopic dermatitis su¦er from 
 eczema in adulthood, at least at times.
Recommendation 
— Informing patients of the chronic and/or 
 recurrent course is recommended.
2.6. Complications
Infections are frequent complications of atopic 
 dermatitis. ese include: 
— Secondary infections with bacteria, 
— Viral infections,
— Fungal infections.
Complications in rare cases are eye diseases (glau-
coma, keratoconus, retinal detachment, blindness), 
alopecia areata and growth delay or small stature 
(due, among other things, to hypoproteinemia as a 
result of exudation of inammatory secretion or 
poor diet or malnutrition). Atopic dermatitis can be 
associated with concomitant ichthyosis vulgaris.
Recommendations
— The complications of atopic dermatitis such as 
 viral (e.g., eczema herpeticum) and bacterial 
(e.g., staphylococcal) superinfections must be 
 familiar to treating clinicians.
— It is recommended to inform (educate) a®ected 
patients and their relatives about possible 
 complications of atopic dermatitis.
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2.7. Diagnosis 
2.7.1. General remarks 
General diagnosis requires a medical history (includ-
ing personal and family atopic history) and examina-
tion of the entire skin, including exact documenta-
tion. A biopsy for dermatohistopathology examina-
tion is indicated in individual cases for di¦erential 
diagnosis. However, other eczema conditions cannot 
be distinguished with certainty histologically.
Recommendations
— As part of general diagnosis, obtaining the 
 medical history (including personal, family and 
occupational atopic history) is recommended.
— It is recommended to examine the entire skin 
 organ. 
— It is recommended to discover possible 
 psychosomatic, dietary or other environmental 
trigger factors. 
— A biopsy for dermatohistopathology 
 examination can be considered for di®erential 
diagnosis. 
— The use of validated criteria for making the 
 diagnosis is recommended when conducting 
 clinical studies.
2.7.2. Comorbidities 
e classic comorbidities of atopic dermatitis are the 
other atopic diseases such as bronchial asthma and 
allergic rhinoconjunctivitis. Food allergies can be a 
trigger factor for atopic dermatitis but the patients 
also oªen exhibit immediate allergic reactions, 
from contact urticaria to anaphylaxis. In addition, 
psychosomatic comorbidities should be noted. 
ere is an association between atopic dermatitis 
and mental illness in adulthood. 
2.7.3. Dierential diagnosis
e most important di¦erential diagnoses are  other 
eczema diseases (allergic contact eczema, irritant 
and toxic contact eczema, microbial eczema) and, 
in adulthood, the eczema stage of cutaneous T cell 
lymphoma. 
Particularly in infancy, seborrheic eczema must 
be distinguished from atopic dermatitis in the dif-
ferential diagnosis when this is suggested by the his-
tory. Rarer di¦erential diagnoses include scabies, 
psoriasis and syndromes and immune deciency 
syndromes that can be associated with eczematous 
skin changes [11].
Recommendations
— When the manifestations of inammatory skin 
disorders are untypical, di®erential diagnoses 
must be investigated, including in childhood. 
— It is recommended to distinguish atopic eczema 
involving the hands and feet from other eczema 
diseases (irritant toxic eczema, contact allergic 
eczema), psoriasis palmoplantaris and tinea of 
the hands and feet.
 2.7.4. Objective determination of severity 
So-called „objective“ skin scores are used to docu-
ment the extent and severity of atopic dermatitis 
 lesions. Objective assessment of severity with labo-
ratory parameters is suitable for investigation of 
 cohorts in clinical studies but not for individual 
 diagnosis.
Recommendations
— In clinical studies, recording of the objective 
 disease severity, disease symptoms, quality of life 
and course is recommended [12, 13]. Use of 
 validated instruments is recommended for 
measuring these disease aspects of atopic 
 dermatitis. The EASI (Eczema Area and Severity 
Index) and objective SCORAD (Scoring Atopic 
Dermatitis) are validated instruments for 
 measuring objective disease severity [13]. 
— Determination of severity using the afore-
mentioned scores can also be considered on an 
individual basis in routine clinical practice. 
— Measurement of laboratory parameters to 
 determine the severity of atopic dermatitis 
 (thymus- and activation-regulated chemokine 
[TARC], eosinophilic cation protein [ECP] etc.) is 
not recommended in routine clinical practice 
and can be considered in the context of clinical 
studies.
2.7.5. Allergy diagnosis 
e importance of allergic reactions in atopic der-
matitis must be examined individually. IgE-medi-
ated sensitization to environmental allergens (pol-
len, animal dander, house dust mites, fungi, foods 
etc.) can oªen be demonstrated. e clinical rele-
vance of the sensitization must be determined indi-
vidually by elimination and/or provocation testing. 
Sensitization alone does not justify any elimination 
or therapeutic measures. 
Recommendation
— It is recommended to note not only diagnosis 
and treatment of the skin but also the typical 
 comorbidities of atopic dermatitis (food allergy, 
asthma, allergic rhinitis).
Allergo J Int 2016; 25: 82–95  85
Skin testing with low molecular weight contact 
allergens can reveal additional allergic contact der-
matitis in patients with refractory atopic dermatitis 
or a more prolonged disease course.
Recommendations 
— Individual allergy testing is recommended in 
 atopic dermatitis depending on the ©ndings and 
history. 
— Prick testing and/or measurement of speci©c IgE 
antibodies is recommended for individual allergy 
diagnostics according to the patient‘s history. 
The clinical relevance of the sensitization must 
be determined individually by means of 
 elimination and/or provocation tests. 
— Skin tests with protein allergens (known as atopy 
patch test) is not recommended in routine 
 diagnostics.
— Skin tests with low molecular weight substances 
to reveal an additional contact allergy is 
 re commended in atopic dermatitis when 
 suggested  clinically or by the history.
2.8. Provocation factors
e status of provocation factors is individually very 
varied. Knowledge of provocation factors and avoid-
ing or reducing them is part of an individual treat-
ment plan.
Recommendation
— It is recommended to identify individual 
 provocation factors. Apart from allergens, these 
include, in particular, skin irritants and also 
 psychological factors, climate inuences and 
hormonal factors.
2.9. Disease costs
Expenditure per patient for the treatment of atopic 
dermatitis is considerable. In combination with the 
high prevalence, the total burden for paying agen-
cies is high. A¦ected patients and families also bear 
not inconsiderable additional private costs, which 
are di¨cult to determine [14]. It is worth mention-
ing that patients with atopic dermatitis show great-
er readiness to pay with the relatively quite reduced 
quality of life [15]. 
Since 2004, the reimburseability of non-pre-
scription medicines has been excluded by the 
 legislature as part of the modernization law on 
 statutory health insurance (GKV). Since then, the 
costs for basic therapeutic agents, even when they 
contain urea, must be met by patients with  atopic 
dermatitis themselves, although their regular 
use is recommended (see 3.1). An exception is 
made for children up to the age of 12 years and 
in those with developmental disorders up to 18 
years.
Recommendation
— Atopic dermatitis is associated with considerable 
direct, indirect and intangible costs. The costly 
basic care for patients is equivalent to basic the-
rapy so it is recommended that the cost be borne 
by the statutory health insurance companies.
2.10. Management, general aspects
e treatment of atopic dermatitis requires a variety 
of measures that should be adapted individually to 
the patient. Treatment of the oªen troublesome pru-
ritus is a particular challenge. 
Recommendations
— It is recommended to take into account the 
 various provocation factors in the treatment of 
atopic dermatitis and integrate them in 
 individual management.
— It is recommended to work out an individual 
treatment plan depending on the patient‘s age 
and the severity and location of the atopic 
 dermatitis. Patient consent and possibly written 
information is appropriate here.
2.11. Occupational dermatology aspects
Special attention should be directed toward pre-
vention strategies for patients with an atopic skin 
diathesis [16]. Individual recommendations regar-
ding skin protection and skin cleaning are neces-
sary. If a treatment contract is granted as a result 
of a dermatologist‘s report, which dermatologists 
or occupational physicians can produce for the 
 accident insurer (employer‘s liability insurance as-
sociation), treatment can be billed through the ac-
cident insurer [17].
Recommendations
— It is recommended to investigate potential 
 occupational trigger factors of atopic dermatitis 
in working patients.
— It is recommended to reduce potential 
 occupational trigger factors of atopic dermatitis 
and/or implement skin preventive measures in 
the area of prevention. 
— If conditions permit, production of a 
dermatologist‘s report is recommended. 
— When advising adolescents, it is recommended 
to address occupational aspects and to consider 
the disease atopic dermatitis in the context of an 
occupational consultation by atopic dermatitis 
therapists. If hand eczema has already occurred 
in adolescence in the context of atopic dermati-
tis, adoption of wet occupations is not recom-
mended.
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2.12. Care structure
Recommendations
— Depending on the severity of the atopic 
 dermatitis and/or diagnostic question (e.g., 
 provocation test with allergens), ambulant,  partly 
 inpatient or fully inpatient treatment is 
 recommended.
— Rehabilitation measures can be considered in 
chronic atopic dermatitis for patients and their 
legal custodians (usually parents). 
— Atopic dermatitis education (for parents,  children 
and adolescents according to the AGNES curricu-
lum or adults) in an ambulant setting or during 
inpatient rehabilitation is recommended.
2.13. Treatment principles in atopic dermatitis
Recommendations
— Depending on the severity of the atopic 
 dermatitis, topical treatment methods and/or 
systemic treatments are recommended. 
— Complementary medicine methods must be 
 evaluated after controlled studies are available, 
and their use can then be considered.
2.14. Step treatment in atopic dermatitis
Recommendations
— It is recommended to implement step treatment 
appropriate to the clinical severity. 
— Depending on skin condition, four treatment 
steps are proposed, based on this international 
recommendation (Fig. 1).
3. Evaluations of single treatment methods 
for drug therapy of atopic dermatitis
3.1. Basic therapy
Basic therapy has special importance in the treat-
ment of atopic dermatitis, as the disturbance of 
the skin barrier, genetically determined or caused 
by the inammation, contributes critically to the 
course of the disease according to current under-
standing and probably can also promote new sen-
sitizations through the skin. In the long version of 
the atopic dermatitis guideline, over 20 clinical 
studies of the e¨cacy of basic therapeutic agents 
in atopic dermatitis are mentioned or summa-
rized.
Recommendations
— The use of basic therapeutic agents for the 
 treatment of atopic dermatitis is recommended. 
— The use of basic therapy appropriate to the skin 
condition (e.g., oily ointment bases on dry skin or 
hydrating oil-in-water emulsions for less dry skin) 
is recommended in atopic dermatitis even in the 
absence of signs of inammation.
— Appropriate skin cleansing including baths as a 
component of basic therapy is recommended.
— It is recommended to prescribe basic therapeutic 
agents that do not contain any frequent contact 
allergens. 
— Addition of urea and glycerin to the basic 
 therapy can be recommended. However, urea is 
not recommended in infants. Prior testing for 
 tolerability is recommended if skin is inamed 
and in small children because of possible 
 irritation.
Fig. 1: Multi-stage treatment concept for atopic dermatitis
Step 4:
Persistent severe eczema
Measures required in the
previous stages 
+
Systemic immunomodulatory
therapy (e.g., ciclosporin A)*
Step 3:
Moderate eczema
Measures required in the previous stages 
+ 
more potent topical glucocorticosteroids
and/or topical calcineurin inhibitors*, **, ***
Step 2:
Mild eczema
Measures required in the previous stages 
+
Weak topical glucocorticosteroids and/or
topical calcineurin inhibitors*, **, ***
Step 1:
Dry skin
Topical basic therapy
Avoidance or reduction of trigger factors 
*UV therapy often is indicated from stage 2 (considering age restrictions UV therapy is not recommen-
ded during childhood). Caution: No combination with ciclosporin A and topical calcineurin inhibitors. 
**First-line therapy: Normally topical glucocorticosteroids; in case of intolerance/non-efficacy and in 
special body areas (face, intertriginous areas, genital area, scalp in infants) use of topical calcineurin in-
hibitors. ***Additional application of anti-pruritic and antiseptic substances can be considered.
(Note: For reasons of clarity Fig. 1 does not list all treatment options discussed in this guideline.)
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3.2. Topical therapy with glucocorticosteroids
Topical glucocorticosteroids have been available for 
50 years for the treatment of acute, subacute and 
chronic eczematous areas; they are divided into four 
classes in Europe as regards their potency (and into 
seven classes in the American literature). In the long 
version of the atopic dermatitis guideline, over 100 
clinical studies of the e¨cacy of topical glucocorti-
costeroids in atopic dermatitis are mentioned or 
summarized, the results of which contributed to the 
recommendations in this guideline.
Recommendations
— The use of topical glucocorticosteroids for anti- 
inammatory treatment is recommended, taking 
into account the bene©t and side e®ect pro©le. 
— Treatment with topical glucocorticosteroids is 
usually recommended once daily, and twice daily 
in exceptional cases. Furthermore, treatment until 
healing of the individual lesions is recommended.
— Long-term daily treatment is not recommended.
— Topical glucocorticosteroids must be used as 
 regards their potency according to the local 
 severity, location and patient‘s age. Escalation of 
the potency is recommended if the e®ect is 
 insu²cient.
— Problem areas for treatment with topical 
 glucocorticosteroids are the face, neck, inter-
triginous areas and scrotum, and in infants and 
toddlers the scalp also because of the increased 
absorption. The increased risk of absorption  under 
occlusion (e. g., in the napkin area) should be con-
sidered.
— It is recommended not to use topical glucocortico-
steroids in these areas for longer than a few days.
— Individual investigation is recommended if there 
is no response of the atopic dermatitis to topical 
glucocorticosteroids (reduced adherence, e. g. 
 because of „fear of cortisone“, unsuitable vehicle, 
allergy to glucocorticosteroids, continuing trigge-
ring of the atopic dermatitis by trigger factors). 
— Temporally limited interval therapy with suitable 
topical glucocorticosteroids (e. g., uticasone 
 propionate, methylprednisolone aceponate) 
 beyond the healing phase is recommended. 
— Following the acute therapy, proactive inter-
mittent follow-up treatment for several months 
(usually three-monthly initially) once or twice a 
week on previously diseased areas can be 
 recommended. 
— Infants and toddlers in particular are more sus-
ceptible with regard to undesirable e®ects. More 
prolonged use of more potent glucocortico-
steroids (class III) is usually not recommended in 
infants and toddlers. The longer-term use of class 
IV glucocorticosteroids (exception: hands, feet) is 
not recommended in all age groups.
3.3. Topical calcineurin antagonists and
3.4. Discussion for oncogenic potential of 
calcineurin inhibitors
Topical calcineurin antagonists have been avail-
able since 2002 for the treatment of atopic derma-
titis. Like treatment with topical glucocorticoste-
roids, they are a symptomatic anti-inammatory 
therapy, though the range of undesirable drug ef-
fects of the two drug groups is di¦erent. In the long 
version of the atopic dermatitis guideline, over 50 
clinical studies of the e¨cacy of topical calci-
neurin antagonists in atopic dermatitis are men-
tioned or summarized, the results of which con-
tributed to the recommendations in this guideline. 
As discussed in more detail in the long version, 
there is no convincing evidence, either from con-
trolled studies with follow-up of patients or from 
studies of patient databases, that calcineurin in-
hibitors can induce malignant disease (squamous 
cell carcinoma, malignant lymphoma) when used 
topically.
Recommendations
— Topical calcineurin inhibitors are recommended 
especially when topical glucocorticosteroids 
 cannot be used or may lead to local irreversible 
undesirable e®ects over the duration of 
 treatment. 
— Because of the undesirable drug e®ect pro©le of 
glucocorticosteroids, calcineurin inhibitors  
can be recommended as ©rst-line-therapy in 
„ problem areas“ (e.g., face, intertriginous areas, 
genital region, scalp in infants). 
— Observation of age restrictions is recommended 
(use only for children aged 2 years or older, and 
use of 0.1 %  tacrolimus only for children and 
 adolescents aged 16 years or older). Use in 
 infants and toddlers can be recommended in an 
individual case, however, especially those with 
severe chronic eczema of the face/cheeks. In  
this situation, informing the parents in detail 
 regarding the o®-label use and bene©t-side 
 e®ect  pro©le is recommended.
— Temporally limited interval therapy with topical 
calcineurin inhibitors beyond the healing phase 
is recommended. 
— Following the acute therapy, proactive inter-
mittent follow-up treatment for several months 
(usually three-monthly initially) twice a week on 
previously diseased areas can be recommended. 
— An e®ective sunscreen is recommended.
— A treatment pause is recommended if cutaneous 
viral infections occur in the treatment area. 
— The combination of topical calcineurin inhibitors 
with phototherapy is not recommended.
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3.5. Antipruritic topical agents and other anti-
inammatory topical agents
3.5.1 Antipruritic agents
Polidocanol: Polidocanol has an anesthetic and anti-
pruritic action. ere are no controlled clinical stud-
ies of formulations containing this substance.  Systemic 
undesirable drug e¦ects have not been described. 
 Polidocanol leads only rarely to contact allergy.
Recommendation 
— No therapy recommendation can be given for 
polidocanol on the basis of controlled studies. 
On the basis of open-label studies and clinical 
experience, supportive antipruritic treatment 
with polidocanol can be considered. The use of 
polidocanol does not replace anti-inammatory 
therapy.
Tannins: e e¦ect of tannins is based on an astringent 
action. In dermatological therapy, both synthetic (e. g., 
topical agents containing tamol) and natural tannins 
(e. g., black tea) are available. ere are no controlled 
studies of the e¦ects of tamol treatment in atopic der-
matitis but only open-label observations of use. 
Recommendation
— No therapy recommendation can be given for 
tannins on the basis of controlled studies. On  
the basis of open-label studies and clinical 
 experience, supportive antipruritic treatment 
with tannins can be considered. The use of 
 tannins does not replace anti-inammatory 
 therapy.
3.5.2. Other anti-inammatory topical agents
Zinc: Topical agents containing zinc have an astrin-
gent, anti-inammatory and cooling e¦ect. 
 However, there are no controlled studies of e¨cacy 
in atopic dermatitis.
Recommendationn
— No therapy recommendation can be given on 
the basis of controlled studies. On the basis of 
general clinical experience, zinc in basic 
 therapeutic agents can be recommended.
Shale oil (bituminosulfonates): Bituminosulfonates 
are a mixture containing approximately 120 di¦er-
ent components, which have anti-inammatory ef-
fects in vitro, among other e¦ects. In the long version, 
a controlled study of e¨cacy is summarized. 
Recommendation
— On the basis of general clinical experience, 
 treatment with shale oils can be considered.
Products containing coal tar: Products containing 
coal tar have been used more and more rarely in re-
cent years for the topical treatment atopic dermati-
tis. In the long version, a controlled study of e¨ca-
cy is summarized. 
Recommendation
— The use of products containing coal tar can be 
considered in exceptional cases (e. g., chronic 
 licheni©ed eczema in adults).
3.6. Antimicrobial and antiseptic substances
3.6.1. Topical and systemic antibiotics
e skin is colonized with Staphylococcus aureus in 
up to 90 % of cases of atopic dermatitis, components 
or secretion products of which are blamed for wors-
ening skin inammation in atopic dermatitis. Staph-
ylococcus aureus is oªen found to be increased on the 
skin of adolescent or adult patients. Moreover, in 
head-neck-shoulder dermatitis sensitization to sap-
rophytes of the Malassezia species is more  commonly 
present. In the long version of the atopic dermatitis 
guideline, several clinical studies of the e¨cacy of an-
tiseptics and two studies of the e¨cacy of antifungal 
agents in atopic dermatitis are mentioned or summa-
rized, the results of which have contributed to the 
recommendations in this guideline.
Recommendations
— If there is no response to topical glucocortico-
steroids/calcineurin inhibitors and/or evident 
 superinfection, the use of an additional antimicro-
bial therapy (topical antiseptic) can be considered 
in chronic recurrent or chronic eczema. 
— Treatment with systemic antibiotics is recommen-
ded in eczema with clear clinical signs of bacterial 
superinfection. On the basis of current resistance 
spectra, cephalexin, which is e®ective exclusively 
against gram-positive bacteria, or another ©rst-
generation cephalosporin can be recommended.
— Longer-term use of topical antibiotics (incl. fusidic 
acid) is not recommended because of the risk of 
development of resistance and also, with some 
 topical antibiotics, because of the risk of sensitiza-
tion.
— Antifungal therapy can be considered for the clini-
cal picture of head-neck-shoulder dermatitis. This 
applies especially for patients with atopic dermati-
tis and marked sensitization to Malassezia species.
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3.6.2. Antimicrobial clothing 
In recent years, the e¨cacy of antimicrobial cloth-
ing coated with silver nitrate or a quaternary 
 ammonium compound has been studied. In the 
long version, ten studies with small patient popula-
tions are summarized.
Recommendation
— Wearing antimicrobial underwear (e. g., under-
wear containing silver nitrate) can be considered 
in chronic atopic dermatitis.
3.7. Antihistamines
A clear therapeutic e¦ect of nonsedating H1 anti-
histamines on the skin condition in atopic derma-
titis cannot be deduced from available clinical 
studies. Comedication with H1 antihistamines 
can be justied in individual cases of atopic der-
matitis because of the reduction of pruritus and 
sedation. If patients exhibit anxiety states aªer 
taking antihistamines, this can be attributable to 
a paradoxical reaction and the product must be 
discontinued. However, due to their highly unfa-
vorable risk-benefit profile, the Commission on 
Drug Safety in Children of the German Society of 
Pediatrics and Adolescent Medicine advises 
against the use of  sedating over-the-counter anti-
histamines (including doxylamine, diphenhydr-
amine, dimenhydrinate (diphenhydramine theo-
phyllinate), and promethazine (Position Paper of 
the Commission on Drug Safety in Children of 
the German Society of Pediatrics and Adolescent 
Medicine 2012 and [18]).
Recommendations
— There is no evidence for the bene©t of H1 antihis-
tamines for the treatment of pruritus in atopic 
dermatitis. In individual cases of severe acute a-
re-ups, H1 antihistamines can be used in combi-
nation with other treatment measures. 
— Use of topical H1 receptor antagonists is not re-
commended.
— H2 antihistamines are not recommended for the 
treatment of atopic dermatitis.
3.8. Mast cell stabilizers (cromoglycate) and 
ketotifen
Oral cromoglycate, nedocromil and ketotifen did 
not shown any therapeutic e¦ect on atopic derma-
titis in clinical studies.
Recommendation
— Mast cell stabilizers and ketotifen are not recom-
mended for the treatment of atopic dermatitis.
3.9. Specic immunotherapy 
Specic immunotherapy with allergens (hyposen-
sitization) has a rm position in the therapy of 
 respiratory allergic diseases (allergic rhinitis, mild 
allergic bronchial asthma) when the clinical rele-
vance of an IgE-mediated sensitization to the 
 allergen is conrmed. From the studies summa-
rized in the long version of the guideline, it can be 
concluded cautiously that subcutaneous specic 
immune therapy with house dust mite allergens 
can probably be e¦ective in a subgroup of highly 
sensitized adult patients with atopic dermatitis; de-
terioration of the atopic dermatitis was not ob-
served in clinical studies with specic immuno-
therapy.
Recommendations
— Subcutaneous speci©c immunotherapy in the 
approved indication (allergic rhinitis, mild 
 allergic bronchial asthma, insect toxin allergy) 
with coexisting atopic dermatitis can be 
r ecommended (see S2 guideline „Speci©c 
 immune therapy with allergens“, [19]). 
— Use of the therapy only because of the atopic 
dermatitis can be considered in severely a®ected 
patients when aerogen-triggered eczema is 
 suspected with corresponding evidence of 
 sensitization.
3.10. Oral glucocorticosteroids 
On the basis of uncontrolled observations (experi-
ence-based knowledge), clear e¨cacy of oral gluco-
corticosteroids can be assumed. 
Recommendations
— Short-term therapy with oral glucocorticosteroids 
to interrupt the acute exacerbation can be 
 considered, especially in the treatment of adult 
patients with severe forms of atopic dermatitis.
— Because of the undesirable drug e®ects, longer-
term treatment of atopic dermatitis with syste-
mic glucocorticosteroids is not recommended.
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3.11. Ciclosporin
Ciclosporin is an immunosuppressant drug licensed 
since 1997 for the treatment of severe atopic derma-
titis in adulthood, and the evidence of e¨cacy is 
very good (see long version). Please refer also to the 
S1 guideline on the use of ciclosporin in dermatol-
ogy; practical aspects are emphasized there in par-
ticular [20].
3.12. Azathioprine 
Azathioprine has been used in Anglo-American 
countries for many years in the treatment of severe 
atopic dermatitis; controlled studies showed e¨ca-
cy in atopic dermatitis. 
Recommendations
— Azathioprine (o®-label) can be considered in ato-
pic dermatitis if ciclosporin is not e®ective or is 
contraindicated.
— Measurement of the enzyme thiopurine methyl-
transferase (TPMT) before initiation of treatment 
is recommended so that the dose can be ad-
justed if necessary to reduce the risk of bone 
 marrow toxicity. A dose of 1–3 mg/kg BW/d is 
 recommended depending on the TPMT activity. 
— Independent of this, the azathioprine dose must 
be reduced to one quarter of the normal dose 
when xanthine oxidase inhibitors such as allopu-
rinol, oxipurinol or thiopurinol are used at the 
same time. 
— Phototherapy is not recommended with azathio-
prine.
— Optimal UV light protection is recommended 
when azathioprine is taken.
3.13. Mycophenolate mofetil
Mycophenolate mofetil (MMF) is licensed as an im-
munosuppressant for the treatment of nephritis in 
systemic lupus erythematosus and in transplant 
medicine; usually open-label clinical studies also in-
dicate e¨cacy in severe atopic dermatitis. 
Recommendation
— Mycophenolate mofetil can be considered in 
 atopic dermatitis in adults at up to 2 g daily, 
 observing the o®-label criteria, if ciclosporin is 
not e®ective or is contraindicated
3.14. Methotrexate 
Methotrexate (MTX) was shown to be e¦ective in 
severe atopic dermatitis in recent controlled studies. 
Recommendation
— Methotrexate (o®-label) can be considered in 
atopic dermatitis if ciclosporin is not e®ective or 
is contraindicated.
Recommendations
— The use of ciclosporin A can be recommended 
for the treatment of chronic severe atopic 
 dermatitis in adulthood. 
— A starting dose of 2.5–3.5, max. 5 mg/kg BW/d in 
two divided doses is recommended. 
— Induction therapy is recommended in atopic 
 dermatitis, with treatment with an e®ective dose 
between 2.5–5 mg/kg BW/d continued until an 
improvement of the dermatosis has been largely 
achieved. It is then recommended to reduce the 
dose gradually. Following response, a dose 
 reduction by 0.5–1.0 mg/kg BW/d at two-weekly 
intervals to the individual maintenance dose can 
be recommended. Before the start of treatment, 
detailed tests of general physical and in particu-
lar nephrological status should be performed.
— If there is a good response, interruption of 
 therapy is recommended after 4–6 months.
— Treatment over a prolonged period can be 
 considered for severe atopic dermatitis (if well 
tolerated). 
— In the treatment of atopic dermatitis with ciclo-
sporin, measurement of the ciclosporin trough 
blood levels is not recommended.
— Ciclosporin can also be considered as a possible 
o®-label option in the treatment of children and 
adolescents who have a refractory and very 
 severe course of atopic dermatitis. 
— Protective vaccinations with live vaccines are not 
recommended during treatment with ciclosporin 
because of the possible absence of successful 
vaccination or because of possible complica-
tions. A treatment break of two weeks before 
and 4–6 weeks after vaccinations must therefore 
be observed.
— Because of the increased carcinogenesis risk, the-
rapy with ciclosporin A must not be combined 
with phototherapy.
— Optimal UV light protection is recommended 
when ciclosporin is taken.
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3.15. Biological agents
3.15.1. Monoclonal anti-IgE antibodies
Anti-IgE (omalizumab) is licensed for the treatment 
of severe allergic bronchial asthma and severe urti-
caria. e e¦ects of treatment in atopic dermatitis 
have been rather disappointing to date. 
Recommendation
— Treatment of atopic dermatitis with omalizumab 
is not recommended.
3.15.2. Other biologicals
On the basis of positive case reports, there is  limited 
experience for the use of ustekinumab, rituximab, 
tocilizumab and alefacept in atopic dermatitis. e 
as yet unlicensed anti-IL4R antibody dupilumab 
was shown to be e¦ective in clinical studies of atop-
ic dermatitis [21].
Recommendation
— Current studies do not allow any assessment of 
biologicals in atopic dermatitis.
3.16. Alitretinoin
Alitretinoin is licensed for the treatment of chronic 
hand eczema and works particularly well in hyper-
keratotic forms. In a published case series, therapy 
e¦ects on coexisting atopic dermatitis were also 
shown.
Recommendation
— The treatment of hand eczema in the licensed 
 indication can also be considered when 
 concomitant atopic dermatitis is present.
4. Non-drug therapy methods
4.1. Phototherapy
Phototherapy has achieved rm status in recent de-
cades. Unlike in other countries such as Great Brit-
ain, the therapy is not linked to clinics in Germany, 
Austria and Switzerland, but is also o¦ered by der-
matologists in private practice.
Recommendations
— Phototherapy (UVA-1 therapy, UVB narrowband 
therapy, UVB broadband therapy, balneo photo-
therapy) can be recommended as adjuvant 
 therapy in acute disease periods of atopic der-
matitis in patients ≥ 18 years. In patients > 12 ye-
ars, phototherapy can be considered. 
— The use of long-wave light (> 380 nm) is not re-
commended for the treatment of atopic dermati-
tis in the absence of controlled studies.
4.2. Immune absorption and 4.3 extracorporeal 
photopheresis
Both methods led to improvement of severe atopic 
dermatitis in smaller published case series (see long 
version).
Recommendation
— Treatment with the aforementioned methods 
can be considered in exceptional cases of very 
severe atopic dermatitis when ciclosporin and 
other immunosuppressants are not e®ective or 
are contraindicated.
4.4. Lactobacilli
In summary, there is no convincing evidence to date 
from controlled studies that probiotics have a posi-
tive e¦ect on the severity and course of atopic der-
matitis. Di¦erent dosages and strains in the studies, 
however, make a nal assessment di¨cult.
Recommendation
— The treatment of atopic dermatitis with lacto-
bacilli cannot be recommended on the basis of 
current studies.
With regard to the prevention of atopic dermati-
tis with lactobacilli please refer to the 2014 AWMF 
guideline by Schäfer et al. [9].
4.5. Atopic dermatitis education
Ambulant atopic dermatitis education was exam-
ined with regard to e¨cacy in an interdisciplinary 
pilot scheme in Germany with the support of the 
Federal Health Ministry (BMG) and the statutory 
health insurers (GKV). On the basis of the results 
of the pilot scheme, the German Federal Associa-
tion of Health Insurance Funds in 2007 recom-
mended meeting the costs for education programs 
for atopic dermatitis; the recommendation was up-
dated in 2014.
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Recommendation
— Structured interdisciplinary atopic dermatitis 
education according to the curriculum of the 
 Arbeitsgemeinschaft Neurodermitisschulung 
(AGNES) e. V. (Atopic dermatitis education wor-
king group) is recommended for legal custodians 
of children in the age group up to 7 years and for 
children (8–12 years) and their legal custodians 
and for patients ≥ 13 years with chronic or  chronic 
recurrent atopic dermatitis.
4.5.1. Self-help organizations
Recommendation
— It is recommended to inform patients with  
atopic dermatitis of existing self-help groups  
and  encourage them to take part. 
4.6. Elimination diets
Roughly half of infants and toddlers with persistent 
eczema also show sensitization to foodstu¦s at the 
same time. Sensitization to foodstu¦s is oªen found 
in older patients also. However, a current clinical 
allergy to food components exists in only a minori-
ty of patients with atopic dermatitis. Dietary inter-
vention in patients with atopic dermatitis,  especially 
a¦ected infants and toddlers, is justied only when 
a current food allergy has been demonstrated. ere 
is no general „atopic dermatitis diet“.
Recommendations
— On general aspects of diagnosing food allergy, 
please refer to the S2 AWMF guideline on food 
allergy (2016). A targeted elimination diet in 
children with atopic dermatitis limited to one to 
two years is recommended if there is a clear 
 history of an immediate type reaction or a clearly 
positive oral provocation test.
— It is recommended to objectively con©rm a late 
reaction (worsening of eczema) after food provo-
cation by a doctor the next day with a severity 
score (SCORAD, EASI or IGA [Investigator’s Global 
Assessment]). Evaluation by patients or their 
 relatives alone cannot be recommended. 
— It is recommended to follow a targeted age- 
appropriate elimination diet after corresponding 
diagnostic tests according to the allergen and 
patient‘s age for an individually determined 
 period. 
— Review of the persistence of a food allergy to 
cow‘s milk, hen‘s eggs and wheat our is recom-
mended after one and two years in children. 
— To avoid dietary errors and ensure a balanced 
diet even with an elimination diet, it is recom-
mended to have the diet supervised by a 
 nutritionist trained in allergy.
4.7. Essential fatty acids 
Against the background of detectably reduced delta- 
6-desaturase activity in atopic dermatitis, a series 
of studies of supplementation with essential n-6 fat-
ty acids was conducted, which did not show any ef-
fects on atopic dermatitis. On the basis of new nd-
ings, the role of n-3 fatty acids has been discussed 
recently but controlled studies are lacking, with the 
exception of one smaller study in which these were 
given intravenously.
Recommendations
— Oral administration or topical application of n-6 
fatty acids in atopic dermatitis cannot be recom-
mended.
— In particular, dietary substitution with borage oil 
or evening primrose oil (gamma-linolenic acid) 
and the topical use of gamma-linolenic acid for 
the treatment of atopic dermatitis with the aim 
of clinical improvement cannot be recommen-
ded in atopic dermatitis.
— The intravenous use of n-3 fatty acids cannot be 
recommended.
4.8. House dust mite reduction
Many patients with atopic dermatitis are sensitized 
particularly obviously to house dust mites. Mea-
sures to reduce house dust mites had some positive 
e¦ects on the skin condition of these patients in 
studies (see long version).
Recommendation
— Encasing can be considered in sensitized 
 patients with atopic dermatitis.
4.9. Psychological treatment
Psychological and emotional factors are regarded as 
relevant inuences in atopic dermatitis even if it is 
not certain to what extent such factors can in turn 
be inuenced by the eczema. In controlled studies, 
behavior therapies have shown e¨cacy in atopic 
dermatitis.
Recommendations
— Psychological therapy can be considered for 
 individual patients with atopic dermatitis. Beha-
vior therapy interventions can be recommended.
— The use of psychological therapy can be recom-
mended only when there is a clear indication 
(psychological factors as individual trigger 
 factors of atopic dermatitis or if the atopic 
derma titis has secondary psychosocial con-
sequences for the patient/family).
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Updating
is updated version of the guideline is valid until 
05/2018.
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